<DOC>
	<DOCNO>NCT01429090</DOCNO>
	<brief_summary>The primary objective study : •To describe extent rate absorption methantheline single oral dose administration Vagantin® coat tablet ( Test ) comparison methantheline bromide solution ( Reference ) The secondary objective study : - To determine elimination half-life methantheline bromide - To describe effect Test Reference salivation , accommodation , pupil response , blood pressure heart rate - ass frequency intensity adverse drug reaction</brief_summary>
	<brief_title>Bioavailability Vagantin® Coated Tablets Relative Oral Methantheline Bromide Solution</brief_title>
	<detailed_description>The quarternary anticholinergic compound methantheline bromide ( diethyl-methyl [ 2- ( 9 xanthenyl carbonyloxy ) ethyl ] ammonium bromide ) market treat neurogenic bladder instability . In comparison atropine , influence parasympathetic nervous transmission ganglionic rather peripheral muscarinic receptor blockade . Clinical effect single therapeutic dos 50-100 mg last 6 hour long atropine . The drug relaxes smooth muscle gastrointestinal urogenital tract . Furthermore , inhibit bronchial , salivary sweat gland secretion , lower production gastric juice disturbs accommodation . There data available pharmacokinetic property methantheline man . However , 25-50 mg intravenous methantheline seem equivalent 50-100 mg p.o . regard pharmacodynamic effect [ Stille 1988 ] . Vagantin® market coated tablet contain 50 mg methantheline bromide . Because particular property methantheline ( narrow therapeutic range , obviously erratic , incomplete irregular absorption ) national international recommendation concern registration drug , Vagantin® must evaluate regard pharmacokinetic property least relative non-formulated form .</detailed_description>
	<mesh_term>Urinary Bladder , Neurogenic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Methantheline</mesh_term>
	<criteria>age : 18 45 year sex : male female ethnic origin : Caucasian body weight : ±20 % normal weight ( Broca ) good health evidence result clinical examination laboratory checkup judge clinical investigator differ clinical relevant way normal state write informed consent know hypersensitivity investigational product adjuvant pollakisurie cardial renal reason megacolon atonia gastrointestinal tract atonia hypotonia urinary bladder tachycardiac arrhythmia subvesical bladder obstruction , especially benign prostatic hypertrophy narrow angle glaucoma glass contact lenses history gastrointestinal disease ( except appendectomy ) history renal and/or hepatic disease disease know modify absorption , metabolism excretion drug investigation liability orthostatic dysregulation , faintings , blackout alcohol consumption 40 g/day smoker 10 cigarette per day special uniform nutritional habit , e.g . vegetarian undercaloric diet less 14 day last acute disease le 14 day last systemic local drug administration 10 time half life respective drug ( except hormonal contraceptive ) blood donation within last two month block period due another clinical study investigational product ; however least 4 week end study 10 time half life respective drug lack willingness inability cooperate adequately HIV HBV drug screen positive perform ( case positive HIVtest , volunteer must inform physician personal conversation ) lactation pregnancy test positive perform</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Accommodation , Ocular</keyword>
	<keyword>Reflex , Pupillary</keyword>
	<keyword>Salivation</keyword>
</DOC>